1. Home
  2. GRNT vs ESPR Comparison

GRNT vs ESPR Comparison

Compare GRNT & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Granite Ridge Resources Inc.

GRNT

Granite Ridge Resources Inc.

HOLD

Current Price

$5.97

Market Cap

662.8M

Sector

Finance

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$2.64

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRNT
ESPR
Founded
2013
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
662.8M
731.9M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
GRNT
ESPR
Price
$5.97
$2.64
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$6.00
$7.60
AVG Volume (30 Days)
996.8K
5.0M
Earning Date
03-05-2026
03-10-2026
Dividend Yield
7.53%
N/A
EPS Growth
28.57
60.71
EPS
0.18
N/A
Revenue
$450,306,000.00
$403,135,000.00
Revenue This Year
$18.12
$2.92
Revenue Next Year
$7.47
N/A
P/E Ratio
$32.44
N/A
Revenue Growth
18.49
21.31
52 Week Low
$4.18
$0.73
52 Week High
$6.59
$4.18

Technical Indicators

Market Signals
Indicator
GRNT
ESPR
Relative Strength Index (RSI) 70.58 42.37
Support Level $5.21 $2.37
Resistance Level $6.59 $3.02
Average True Range (ATR) 0.18 0.18
MACD 0.06 0.04
Stochastic Oscillator 91.98 53.47

Price Performance

Historical Comparison
GRNT
ESPR

About GRNT Granite Ridge Resources Inc.

Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: